FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab | The Gentleman Report
The Gentleman Report — On Monday, a panel of unbiased advisers to america Meals and Drug Management voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to sluggish the development
